Why Is Silo Pharma (SILO) Stock Up 123% Today?
- Silo Pharma (NASDAQ: SILO ) stock is rocketing higher on Tuesday after the developmental stage biopharmaceutical company secured a new global license. This license covers the development, manufacturing, and commercialization of its Alzheimer's drug SPC-14.
- 07/16/2024
|
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
- Agreement enhances Company's intellectual property portfolio SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer's drug SPC-14. Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs.
- 07/16/2024
|
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
- Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has awarded a contract to its contract research organization (CRO) partner AmplifyBio for an investigational new drug (IND)-enabling large animal GLP (Good Laboratory Practice) study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). The 4-week GLP study will evaluate a 28-day repeat intranasal dosing with a 14-day recovery.
- 06/26/2024
|
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
- Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company's SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. An ongoing pre-clinical research study of SP-26 is underway involving analytical testing services and small batch proof-of-concept extrusion trials for the ketamine hydrochloride (ketamine HCL) implants at 20% and 40% drug load.
- 06/07/2024
|
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 917,432 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.18 per share (or per common stock equivalent in lieu thereof). In a concurrent private placement, the Company issued unregistered warrants to purchase up to 917,432 shares of common stock at an exercise price of $2.06 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.
- 06/06/2024
|
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
- Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its submission of a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the U.S. Food and Drug Administration (FDA) for SPC-15, Silo's intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder. Pre-clinical data indicate that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels.
- 06/04/2024
|
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
- The study has identified a potentially new drug formulation that could potentially extend the period of remission and prevent relapse in patients with depression.
- 05/21/2024
|
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
- Silo's SP-26 currently in development utilizes ketamine as primary therapeutic agent Silo's SP-26 currently in development utilizes ketamine as primary therapeutic agent
- 05/14/2024
|
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). The PK study was conducted as part of non-GLP small animal dose-ranging study of SPC-15 completed in February 2024.
- 04/23/2024
|
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
- SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license Alzheimer's disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021. Under the terms of the license agreement currently in process, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-14 worldwide upon consummation of such agreement.
- 04/10/2024
|
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
- Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain' with the United States Patent and Trademark Office (USPTO). The patent application includes protection for the Company's SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia.
- 03/18/2024
|
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
- All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.
- 02/28/2024
|
Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
- Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
- 02/14/2024
|
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
- Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.
- 02/01/2024
|
Silo Pharma Announces Positive Results in Alzheimer's Disease Study
- Preclinical study shows SPC-14's effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer's disease therapeutic SPC-14 showed positive efficacy in small animals.
- 01/24/2024
|
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
- Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.
- 01/04/2024
|
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
- Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26, which is being developed as a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. In collaboration with Sever Pharma Solutions, Silo's contract development and manufacturing partner, SP-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
- 12/28/2023
|
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
- MedSpray's patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer's disease, and anorexia ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15. “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
- 11/21/2023
|
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
- Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial
- 11/08/2023
|
Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
- Human tissue study assessed SPU-21's efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
- 10/16/2023
|
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
- Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will evaluate the human factor interface and usability of SPC-15's intranasal formulation in combination with a nose-to-brain delivery mechanism.
- 10/11/2023
|
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
- Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA).
- 09/20/2023
|
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
- Investigational New Drug (IND) submission to FDA on target for Q1 2024
- 09/12/2023
|
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
- Clarivate will monitor, manage, and maintain Company's expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™ , a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company's intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.
- 08/10/2023
|
Silo Pharma shares take off as anxiety and PTSD therapeutic candidate achieves milestone
- Silo Pharma shares rose on Tuesday after the development stage biopharmaceutical company announced it has advanced the formulation development of its therapeutic candidate SPC-15, achieving a liquid nasal formulation. This formulation of SPC-15, a targeted prophylactic treatment using ketamine compositions, is being investigated as a method of treatment and prevention of anxiety, post-traumatic stress disorder (PTSD) and other stress disorders.
- 08/08/2023
|
Silo Pharma to Present at Psychedelic Drug Development Conference
- ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D., Vice President of R&D, will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference being held May 15-16, 2023, in person, at the Hilton San Francisco Airport Bayfront in Burlingame, CA.
- 04/24/2023
|
7 Top Penny Stocks To Watch With Big News This Week
- Penny Stocks With News Light Up The Scanners This Week This week
- 01/31/2023
|
3 Essential Strategies for Penny Stocks Trading in 2023
- Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/31/2022
|
Best Penny Stocks To Buy Before 2023? 4 To Watch Now
- Penny stocks to watch this week with news before 2023. The post Best Penny Stocks To Buy Before 2023?
- 12/30/2022
|
7 Millionaire-Maker Stocks You Will Regret Not Buying This Year
- Although the concept of millionaire-maker stocks will always attract attention, at the moment, investors must realize the rules have changed. Fundamentally, the Federal Reserve remains committed to attacking the inflation crisis through hiking the benchmark interest rate.
- 11/17/2022
|
What Is Going on With Silo Pharma (SILO) Stock Today?
- Silo Pharma (NASDAQ: SILO ) stock is falling on Thursday despite the company releasing positive data from a pre-clinical study. This data covers the use of SPC-14 as a therapeutic treatment for Alzheimer's disease.
- 10/20/2022
|
What Is Going on With Silo Pharma (SILO) Stock Today?
- Source: Bukhta Yurii / Shutterstock.com Silo Pharma (NASDAQ: SILO ) stock is in the news Wednesday as investors react to the company uplisting shares. This saw shares of SILO stock switch from the OTC Market to the Nasdaq Exchange yesterday.
- 09/28/2022
|
Can Silo Pharma (SILO) Stock Be a Hot Nasdaq Debut?
- In today's turbulent market, what was once green is now red for many companies across all major indices. That said, among today's bigger losers is Silo Pharma (NASDAQ: SILO ), as this early-stage biotech stock is set for its Nasdaq initial public offering (IPO).
- 09/27/2022
|
Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
- Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine.
- 10/07/2021
|
Silo Pharma Advances Psychedelic Patent Portfolio
- Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
- 08/25/2021
|
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
- Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo's joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control.
- 08/11/2021
|
Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent
- Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin
- 07/27/2021
|
Silo Pharma To Appear On National Media Broadcast on Psychedelics
- Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has announced that the company will be participating in a nationwide media tour on Thursday, July 22 from 8 a.m. – 11:30 a.m. EST.
- 07/21/2021
|
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
- Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Englewood Cliffs NJ, July 09, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore.
- 07/12/2021
|
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
- Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine
- 07/12/2021
|
Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide
- Englewood Cliffs NJ, July 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as “Joint-homing peptides for use in the investigation and treatment of arthritogenic processes.”
- 07/07/2021
|
Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson's and Bipolar Patients
- Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson's, Bipolar disorder, and chronic back pain.
- 06/08/2021
|
Silo Pharma Submits Application for NASDAQ up-listing
- Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to list on the NASDAQ Capital Market (“NASDAQ”).
- 05/25/2021
|
Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review.
- Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review in the Netherlands. Eric Weisblum, CEO of Silo Pharma stated “We are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.”
- 05/13/2021
|
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI's Z-pod™ technology for the transdermal time released delivery of therapeutics
- Sustained Transdermal Delivery Method May Be Key for Alzheimer's and Parkinson's Patients with Dysphagia (difficulty swallowing) Sustained Transdermal Delivery Method May Be Key for Alzheimer's and Parkinson's Patients with Dysphagia (difficulty swallowing)
- 04/28/2021
|
Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ
- Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist to the NASDAQ.
- 04/22/2021
|
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
- Agreement to explore the use of Silo Pharma's Novel Peptide
- 04/07/2021
|
Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis
- Silo Plans to explore the use of Psychedelics to Target Inflammation Silo Plans to explore the use of Psychedelics to Target Inflammation
- 03/04/2021
|
Silo Pharma to Present at Proactive's One2One Virtual Investor Forum
- Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactive's One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST.
- 02/23/2021
|
Aion Therapeutic: Meet the team using artificial intelligence to create a full lineup of psychedelic and cannabis therapies
- Aion Therapeutic Inc (CSE:AION), Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) and Silo Pharma Inc (OTCMKTS:SILO) are presenting at Proactive's next virtual showcase event on February 23. The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1 PM ET.
- 02/22/2021
|
Silo Pharma: Meet the team bridging the gap between traditional pharmaceuticals and psychedelic therapies
- Silo Pharma Inc (OTCMKTS:SILO) will be presenting with Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) at Proactive's next virtual showcase event on February 23. The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1 PM ET.
- 02/18/2021
|
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds
- Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space
- 02/10/2021
|
Silo Pharma Inc. Engages CFN Enterprises Inc. to Reach Psychedelics Investor Audience
- Silo Pharma Inc. is a biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to address underserved medical conditions.Whitefish, Montana--(Newsfile Corp. - February 10, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of Silo Pharma Inc. (OTCQB: SILO) to its growing cannabis and psychedelics client roster.
- 02/10/2021
|
Silo Pharma Inc. Discusses The Potential of Merging Traditional Therapeutics with Psychedelic Research On The Stock Day Podcast
- Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly. "Personally, I have over 20 years of experience investing and working in the private and...
- 01/20/2021
|
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
- Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma's patent applications relates to using a novel peptide with Psilocybin as a therapeutic.
- 01/06/2021
|
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham
- NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board.
- 12/07/2020
|
Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets
- NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has been requested by the OTC Markets Group (“the OTC Markets”) to comment on recent promotional activity.
- 12/04/2020
|
Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco
- NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D. to its newly formed Scientific Advisory Board.
- 11/16/2020
|
Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Dr. Matthew Johnson of John Hopkins University
- Industry Recognized Expert in Psychedelics and Related Safety Guidelines Industry Recognized Expert in Psychedelics and Related Safety Guidelines
- 11/09/2020
|
